Treatment systems, methods, and pharmaceuticals

A combination of Low-Dose Naltrexone, Methocarbamol, and nutraceuticals with a wearable device and remote portal provides a holistic treatment for PTSD and addiction, addressing current treatment inadequacies by modulating the immune system and promoting mood regulation, enhancing mental health management.

WO2026044047A1PCT designated stage Publication Date: 2026-02-26ATHENA GTX
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/042867
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-08-20
Filing Date
2025-08-20
Publication Date
2026-02-26

AI Technical Summary

Technical Problem

Current treatments for mental health issues such as PTSD and addiction are inadequate, with many individuals going unreported and untreated, leading to severe consequences including addiction and suicidal ideation, and existing medications like Low-Dose Naltrexone (LDN) and Cyclobenzaprine have limited efficacy and safety concerns.

Method used

A comprehensive treatment system combining Low-Dose Naltrexone, a muscle relaxant like Methocarbamol, and nutraceuticals such as THC, CBG, and CBD, along with a wearable device and remote patient portal for continuous monitoring and therapy access, providing a holistic approach to mental health management.

Benefits of technology

The system offers safe and effective relief for mental health issues by modulating the immune system, reducing inflammation, and promoting mood regulation, while enabling continuous monitoring and therapy access, thereby reducing the need for narcotics and improving overall well-being.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000025_0001
    Figure IMGF000025_0001
  • Figure IMGF000027_0001
    Figure IMGF000027_0001
  • Figure 00000036_0000
    Figure 00000036_0000
Patent Text Reader

Abstract

Mental health treatment systems and methods include a pharmaceutical, a nutraceutical, a wearable patient monitoring device, and a remote patient portal adapted to receive data from the patient monitoring device. The patient portal provides the patient access to health professionals and health materials.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] TREATMENT SYSTEMS, METHODS, AND PHARMACEUTICALS

[0002] Reference to Related Applications

[0003] The present application claims priority to Provisional U.S. Application No. 63 / 685,213, filed August 20, 2024, entitled “TREATMENT SYSTEMS, METHODS, AND PHARMACEUTICALS,” and is incorporated herein in its entirety.

[0004] Background

[0005] 1. Field of the Invention

[0006] The invention is directed to a pharmaceutical treatment for mental health coupled with a treatment portal for the patient having 24 / 7 monitoring and therapies.

[0007] 2. Description of the Background

[0008] Anyone struggling with addiction to drugs or alcohol, or suffering from Post- traumatic stress disorder (PTSD), or both, will benefit from treatment; but the key to success is that the patient knows they have issues, seeks help, and believes treatment will be of benefit. Adjunctive medical and psychological support can be crucial to prevent progression to more serious consequences including suicide.

[0009] About 5 out of every 100 adults (or 5%) in the U.S. have PTSD. In 2020, that number was about 13 million Americans. Women are more likely to develop PTSD than men. About 8 of every 100 women (or 8%) and 4 of every 100 men (or 4%) are treated for PTSD. PTSD is also more common among Veterans than civilians. At some point in their life, 7 out of every 100 Veterans (or 7%) will have PTSD. PTSD is also more common among female Veterans (13 out of 100, or 13%) versus male Veterans.

[0010] Most PTSD patients go unreported and never seek help. Sadly, many develop addiction issues and suicidal ideation. Addiction is a chronic mental disorder that affects the brain and involves motivation and reward. It is the inability to stop using a substance or engaging in behaviors, despite knowing they often cause physical and psychological harm. Drug and alcohol addiction impacts millions of Americans each year. Nationwide, alcohol claims around 88,000 lives each year in the U.S. This makes alcohol the third leading cause of preventable deaths in the United States. Approximately 20% of Americans (53 million people) report using illegal drugs or misusing prescription drugs. Among the Americans who use illegal drugs, roughly 25% have a substance use disorder (SUD). More than 20 million people in the U.S. have an addiction. Yet only 10% of these people receive any addiction treatment. Drug and alcohol addiction costs the United States an estimated $600 billion each year.

[0011] Some Sobering Facts:

[0012] • About 31% of all service members develop PTSD after returning from combat (nearly 1 in 3).

[0013] • More than 10% of all US veterans have been diagnosed with a substance abuse disorder (SUD).

[0014] • For 20 consecutive years, the US has exceed 6,000 veteran deaths by suicide / year ( 16+ / day ) .

[0015] • Veterans are at 57% higher risk of suicide than those who haven't served.

[0016] • The suicide rate for LGBTQ+ community veterans is 7X higher than non-LGBTQ veterans.

[0017] • DAV reported a 1.8% increase in veteran suicides from 2020 to 2021 after seeing a drop each of the two years prior. Particularly alarming is that the suicide rate among women veterans jumped 24.1% — far greater than the 6.3% increase among male veterans.

[0018] • The rate of suicide among veterans may be more than double what federal officials report annually because of undercounting related to drug overdose deaths, misclassed accidents and service record errors.

[0019] • In a recent study, a review of census death data from 2014 to 2018 for only eight of the fifty states and found thousands of suspected or confirmed suicides not included in federal calculations.

[0020] Low Dose Naltrexone (LDN) is a medication that has gained significant attention for its potential benefits in various health conditions, including diverse mental health disorders. Originally developed to treat opioid addiction, Naltrexone is used in much lower doses for its off-label applications. The FDA first approved Naltrexone for use in treating opioid addiction forty years ago in 1984. This approval was for the standard dosage of 50 mg, which is much higher than the doses used in Low Dose Naltrexone (LDN) therapy of 5mg on average. The concept of using Naltrexone at lower doses for various off-label uses, including for mental health conditions, developed later.

[0021] At low doses, Naltrexone is thought to work much differently and at significantly lower risk than at higher doses. It may influence the body's opioid receptors in a way that modulates the immune system and reduces inflammation. This action might have various effects on mental health, potentially improving mood and reducing symptoms of certain conditions. Mood is a fundamental aspect of mental health, playing a key role in diagnosing, understanding, and treating mental health conditions. Mood’s influence extends to various areas of life, including daily functioning, relationships, and overall quality of life. Managing mood effectively through therapy, medication, and self-care is vital for achieving and maintaining good mental health.

[0022] Studies:

[0023] Depression and Anxiety: Some studies suggest that LDN might help with symptoms of depression and anxiety, possibly due to its effects on mood regulation and inflammation. However, evidence is still emerging, and more research is needed to establish its efficacy and safety for these conditions.

[0024] Post-Traumatic Stress Disorder (PTSD): There’s ongoing research into LDN’s potential benefits for PTSD. Some preliminary findings suggest it might help with symptoms related to trauma and stress.

[0025] Autism Spectrum Disorders: LDN is being investigated for its impact on autism, with some research indicating potential benefits in reducing some symptoms or improving overall function.

[0026] While there is promising anecdotal evidence and some preliminary research suggesting LDN might be beneficial for certain mental health conditions, more large- scale, rigorous studies are needed to confirm these findings. Current research is somewhat limited and often involves small sample sizes. LDN is generally well- tolerated, with side effects being relatively mild compared to some other medications. Common side effects may include sleep disturbances, vivid drcams, or gastrointestinal symptoms. However, as with any medication, individual responses can vary. In summary, while there’s growing interest in LDN for mental health applications, more research is needed to fully understand its benefits and limitations.

[0027] In existing LDN+ formulations, the use of the muscle relaxant Cyclobenzaprine is included, and also in low dose. Cyclobenzaprine is a muscle relaxant commonly prescribed to relieve muscle spasms and discomfort associated with acute musculoskeletal conditions and injuries. It’s generally intended for short-term use, z.e., injury pain, and often alongside physical therapy and rest. Cyclobenzaprine works by acting on the central nervous system, particularly in the brainstem. It is thought to decrease the activity of certain neurotransmitters involved in muscle tone and motor control.

[0028] Typical Doses: The usual starting dose is 5 mg taken three times a day, which can be increased to 10 mg if needed. The medication is available in both immediate- release and extended-release formulations. It is typically used for a few weeks, as longterm use can lead to side effects or decreased effectiveness.

[0029] Side Effects: Drowsiness, dizziness, dry mouth, fatigue, and gastrointestinal disturbances. Rarely, it can cause more severe effects like confusion, hallucinations, or irregular heartbeat. It should be used with caution in individuals with certain medical conditions, such as heart problems or glaucoma.

[0030] Interactions: Cyclobenzaprine can interact with other medications, including antidepressants, which can increase the risk of serotonin syndrome. As addiction is one of the key issues in PTSD, use of Cyclobenzaprine is not recommended for people with a history of certain medical conditions or for use in combination with alcohol or other central nervous system depressants. Cyclobenzaprine is effective for short-term relief of muscle spasticity, but it’s side effects strongly suggest continuous monitoring of mental health patients, especially those with addiction issues. Summary

[0031] The present invention overcomes the problems and disadvantages associated with current strategies and designs and provides new tools and methods for mental health treatment.

[0032] A preferred embodiment of the invention is directed to a mental health treatment system. The system includes a pharmaceutical, a nutraceutical, a wearable patient monitoring device, and a remote patient portal adapted to receive data from the patient monitoring device. The patient portal provides the patient access to health professionals and health materials.

[0033] In a preferred embodiment the pharmaceutical comprises a Low-Dose Naltrexone (LDN) and a muscle relaxant. The muscle relaxant is preferably one of Methocarbamol and Cyclobenzaprine. The nutraceutical is preferably comprised of at least one derivative of cannabis. Preferably the nutraceutical comprises at least one of THC (tetrahydrocannabinol), CBG (cannabigerol) and CBD (cannabidiol).

[0034] Preferably, the wearable comprises at least one sensor, each sensor adapted to obtain at least one of skin temperature, SpO2, heart rate (HR), and respiration rate (RR) data. In a preferred embodiment, the wearable comprises at least one of an audible, physical, or optical alarm adapted to alert the patient to data outside a predetermined threshold. The patient portal is preferably Internet accessible. Preferably, the patient portal provides the patient with at least one of health monitoring, medication tracking, medical and / or psychological professional consultations, and access to recordings and / or live streams of exercise classes, physical therapy exercises, mindfulness exercises, breathing exercises, and meditation exercises.

[0035] Preferably a daily dose of the pharmaceutical is comprised of 4.5 mg of methocarbamol and 4.5 mg of low-dose naltrexone (LDN), and a daily dose of the nutraceutical is comprised of 3.04 mg THC, 2 mg of CBG, and 1 mg of CBD. At least one of the pharmaceutical and the nutraceutical preferably comprises a natural cinnamon (Ceylon) filler.

[0036] Another embodiment of the invention comprises a method of treating mental health, comprising the steps of: prescribing a pharmaceutical to the patient, prescribing a nutraceutical to the patient, providing a wearable patient monitoring device to the patient, and providing a remote patient portal adapted to receive data from the patient monitoring device. The patient portal provides the patient access to health professionals and health materials.

[0037] Preferably, the pharmaceutical comprises a Low-Dose Naltrexone (LDN) and a muscle relaxant. In a preferred embodiment, the muscle relaxant is one of Methocarbamol and Cyclobenzaprine. The nutraceutical is preferably comprised of at least one derivative of cannabis. Preferably, the nutraceutical comprises at least one of THC (tetrahydrocannabinol), CBG (cannabigerol) and CBD (cannabidiol).

[0038] In a preferred embodiment, the wearable comprises at least one sensor, each sensor adapted to obtain at least one of skin temperature, SpO2, heart rate (HR), and respiration rate (RR) data. Preferably, the wearable comprises at least one of an audible, physical, or optical alarm adapted to alert the patient to data outside a predetermined threshold. The patient portal is preferably Internet accessible. Preferably, the patient portal provides the patient with at least one of health monitoring, medication tracking, medical and / or psychological professional consultations, and access to recordings and / or live streams of exercise classes, physical therapy exercises, mindfulness exercises, breathing exercises, and meditation exercises.

[0039] Preferably, a daily dose of the pharmaceutical is comprised of 4.5 mg of methocarbamol and 4.5 mg of low-dose naltrexone (LDN), and a daily dose of the nutraceutical is comprised of 3.04 mg THC, 2 mg of CBG, and 1 mg of CBD. At least one of the pharmaceutical and the nutraceutical preferably comprises a natural cinnamon (Ceylon) filler.

[0040] Other embodiments and advantages of the invention are set forth in part in the description, which follows, and in part, may be obvious from this description, or may be learned from the practice of the invention.

[0041] Description of the Figures

[0042] Figure 1 depicts an example of heart rate changes and the participant’ s fatigue and recovery.

[0043] Figure 2 depicts a chart of a decreased cognition model based on the level of SpO2. Figure 3 depicts a participant’s representative data plot of stability prior to trial initiation. Figure 4 depicts a participant’s data file pre- and post-therapy, pre- and post-therapy divided by black vertical dashed line.

[0044] Figure 5 depicts the data of the same participant as in figure 4, showing a volatility abrupt change in data files after treatment starts depicted by the vertical black dotted line on Day 5.

[0045] Figure 6 depicts a chart of a patient’ s data with trending lines statistically inserted. Figure 7 depicts a chart of the volatility in a participants data file.

[0046] Description of the Invention

[0047] As embodied and broadly described herein, the disclosures herein provide detailed embodiments of the invention. However, the disclosed embodiments are merely exemplary of the invention that may be embodied in various and alternative forms. Therefore, there is no intent that specific structural and functional details should be limiting, but rather the intention is that they provide a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention.

[0048] In the present invention the use of LDN is preferably used in conjunction with another more modern muscle relaxant but with added improved pain reduction. For example, Methocarbamol (Robaxin®) is a muscle relaxant used to treat muscle spasms and discomfort associated with musculoskeletal conditions. Although the clinical effectiveness of Methocarbamol is not well known as compared to Cyclobenzaprine (which is well studied) it offers significant advantages. For example, Methocarbamol is prescribed to relieve muscle spasms and associated pain, often used in conjunction with physical therapy and rest. It’s typically used as an adjunct to other therapies for managing acute muscle pain and discomfort.

[0049] Methocarbamol acts on the central nervous system (CNS), though its exact mechanism of action isn’t fully understood. It is believed to depress the central nervous system to produce muscle relaxation and reduce pain. Since relaxation and pain reduction have been found to be helpful in lessening the PTSD cycle of mental health deterioration, it is more suited for use in patients with chronic disease who seek alleviation over long periods of time. Typical Doses: Initial therapeutic dosing is often 1 ,500 mg to 2,000 mg taken 4 times a day. The dose may be reduced after a few days to a maintenance dose of 750 mg to 1,000 mg taken 3 to 4 times daily. Methocarbamol is currently FDA cleared for patient use, and now available in both oral tablets and injectable forms. Preferably, in the formulation disclosed herein, the dosage is reduced to about 5 mg. However, it can be lower, for example as low as 1 mg, or higher, for example 50 mg, 100 mg, 200 mg, or another dosage.

[0050] Side Effects. Side Effects are drowsiness, dizziness, lightheadedness, and gastrointestinal issues such as nausea or upset stomach. Rare but more serious side effects can include allergic reactions, severe dizziness, or unusual tiredness.

[0051] Interactions and Precautions. Methocarbamol can interact with other medications, especially CNS depressants, which may enhance patient drowsiness or other side effects. Caution is advised in people with a history of liver problems, as the medication is metabolized by the liver. In severe long term alcohol addiction, use of Methocarbamol at even 5 mg may need to be adjusted. It should be used with caution in individuals with a history of drug abuse and / or who are pregnant or breastfeeding.

[0052] In the present invention, the alternative formulation may also include alkaloids, flavonoids and glycosides which boost therapeutic efficacy via anti-inflammatory, analgesic, antioxidant and antimicrobial properties.

[0053] Crepe jasmine is one potential additive to the formulation. Crepe jasmine, also known as Tabernaemontana divaricata, is a plant native to tropical regions and commonly for its ornamental value. However, it has been known to be used in traditional medicine and has significant advantages. Conolidine, a natural compound found in the bark of crepe jasmine, can alternately be used.

[0054] In traditional medicine systems, particularly in parts of Asia, crepe jasmine has been used for a variety of ailments. For example, for reducing inflammation and managing pain. Some traditional uses involve its application in treating infections due to its antimicrobial properties. Research has shown that extracts from the plant may have antimicrobial properties against certain bacteria and fungi. It has been used for digestive issues, including treating ulcers and gastrointestinal problems. Crepe jasmine contains several active compounds, including Alkaloid compounds known for various biological activities, including potential anti-inflammatory and analgesic effects, and Flavonoids and Glycosides which arc reported to contribute to the plant's antioxidant and antimicrobial properties.

[0055] Despite some promising findings, there is limited clinical evidence supporting the efficacy of Crepe jasmine for specific medical conditions. Most studies are preliminary and involve animal models or in vitro tests rather than human clinical trials. Furthermore, the safety profile of Crepe jasmine, particularly in the context of longterm use or high doses, is not well-documented. Traditional use does not always translate to safety in modern clinical practice. There is limited information on the potential toxicity of Crepe jasmine, especially at higher doses or with prolonged use.

[0056] As of now, Crepe jasmine is not approved by major health regulatory agencies like the FDA for any medical uses. Its application remains largely within the realm of traditional medicine and herbal remedies. Crepe jasmine’s nutraceutical drug formulations are not standardized or widely established in modem pharmaceutical practices. However, various traditional and folk medicine practices use different parts of the plant in various forms.

[0057] Herbal Extracts: Tinctures: Alcohol-based extracts of the plant’s leaves, flowers, or roots may be prepared and used for various therapeutic purposes. Infusions: The plant material is steeped in hot water to make teas or infusions that are consumed for their purported health benefits. Decoctions: The plant parts are boiled in water to extract active compounds. This method is used for creating concentrated solutions that can be consumed or applied topically. Poultices and Pastes as a Topical Application: Crushed or powdered parts of the plant can be mixed with other substances to create a paste or poultice for application to the skin. This is traditionally used for treating wounds, sores, or inflammation. Infused Oils: The plant may be used to infuse oils, which can be applied to the skin for its potential anti-inflammatory or analgesic effects. Medicinal Ointments: Prepared by combining plant extracts with a fatty base, used for topical application.

[0058] While modern pharmaceutical formulations of crepe jasmine are not well- established, research and herbal medicine practitioners may use various extraction methods to study its potential medicinal properties. Some possible modem formulations could include: standard extracts to contain specific levels of active compounds, used in research or in herbal supplements. These would be used to ensure consistent dosing and potency. When commercialized, crepe jasmine could be formulated into capsules or tablets containing powdered plant material or standardized extracts. Creams or gels containing extracts from crepe jasmine could be developed for topical use, potentially for anti-inflammatory or analgesic purposes.

[0059] “Magic mushrooms,” also known as Psilocybin Mushrooms, contain the psychoactive compounds psilocybin and psilocin and may be included in the pharmaceutical disclosed herein. These mushrooms are used for their hallucinogenic and psychedelic effects. The formulation of magic mushrooms refers to the natural state and preparation methods, rather than a standardized pharmaceutical formulation.

[0060] Psilocybin is a naturally occurring psychedelic compound that is converted into psilocin in the body. Psilocybin is responsible for the primary psychoactive effects of magic mushrooms, including altered perception, hallucinations, and changes in thought processes. Psilocin is the active form of psilocybin after it is metabolized. Psilocin acts on serotonin receptors in the brain, contributing to the psychedelic effects.

[0061] In some embodiments, Cannabidiol (CBD) and / or Cannabinol (CBN) are included in the formulation. These are compounds derived from cannabis that have garnered attention for their potential therapeutic benefits, including applications in mental health. Preferably CBD and / or CBN can be used as an adjunctive therapy.

[0062] Cannabidiol (CBD)

[0063] Non-Psychoactive: CBD is a non-psychoactive compound, meaning it doesn’t produce the "high" associated with cannabis. It’s primarily extracted from hemp plants. With the recent dismissal by the FDA of MDMA (3,4- Methylenedioxymethamphetamine, commonly known as ecstasy) and pending issues with FDA clearance of magic mushrooms, both psychoactive compounds, CBD offers a tremendously improved alternative. CBD’s legality varies by region, but it is often legal when derived from hemp and contains less than 0.3% THC (tetrahydrocannabinol).

[0064] Potential Mental Health Benefits: Significantly growing evidence suggests that CBD may help reduce anxiety. Research indicates it might influence serotonin receptors in the brain, similar to psilocin, which are involved in regulating mood and anxiety. Clinical trials have shown mixed results, but some participants with anxiety disorders have consistently reported improvements in symptoms. CBD may have antidepressant- like effects due to its impact on serotonin and other neurotransmitter systems. Preliminary studies and animal research indicate potential antidepressant effects, but more robust human trials are needed. CBD has been explored for its potential to improve sleep quality and reduce insomnia. It may help with conditions like anxiety or chronic pain that interfere with sleep, and improved sleep patterns, but clinical evidence is still limited. CBD might help manage PTSD symptoms by affecting endocannabinoid system functions and reducing anxiety. CBD is generally considered safe and well-tolerated, but it can cause side effects like dry mouth, dizziness, or changes in appetite.

[0065] CBN, on the other hand, is a mildly psychoactive compound, but it is much less potent than THC. It’s typically found in aged cannabis or produced as THC degrades. Research on CBN is less extensive compared to CBD, and its potential therapeutic benefits are still being explored.

[0066] CBN is often touted for its potential to promote sleep. It may have sedative properties that could be useful for managing insomnia. Some studies and anecdotal evidence suggest CBN might help with sleep disorders, but scientific research is still limited. There is some preliminary research suggesting that CBN might have anxiolytic effects, though this is less established than the research on CBD. More research is needed to confirm its effectiveness and safety for anxiety and stress management. Because research on CBN is less developed, the full range of side effects and safety profile is not well-documented. Initial indications suggest that it may have a favorable safety profile similar to other cannabinoids.

[0067] CBD has more established potential benefits for mental health, including anxiety reduction, possible antidepressant effects, and sleep improvement. It is generally considered safe, though interactions with medications should be monitored. CBN shows promise, particularly as a sleep aid, but more research is needed to fully understand its benefits and safety profile. Both CBD and CBN hold potential for mental health therapies. Ongoing research will provide more clarity on their efficacy and optimal usage. The pharmaceutical described herein and the adjunct therapies / formulations can be compounded with fillers that arc inert or arc not inert and offer health benefits. One such filler is Cinnamon. Cinnamon is a spice derived from the inner bark of trees belonging to the genus Cinnamomum. It's widely used both as a culinary ingredient and in traditional medicine. Cinnamon has two main types that are commonly used: Ceylon Cinnamon (True Cinnamon, Cinnamomum verum), and Cassia Cinnamon (Cinnamomum cassia).

[0068] Cinnamon has been used to alleviate digestive discomfort, including indigestion, bloating, and gas. It's known for its potential anti-inflammatory and antioxidant properties. Some traditional uses include managing blood sugar levels and supporting overall metabolic health. Some newer information suggests dysregulation of blood glucose in traumatic brain injury patients has been noted.

[0069] Cinnamon is available in various supplement forms, including capsules, powders, and extracts. Cinnamon essential oil is used in aromatherapy and for its antimicrobial properties. It can also be used in topical applications, though it should be used with caution due to its potency. Cinnamon contains antioxidants like polyphenols that help protect cells from oxidative damage. Its compounds can reduce inflammation in the body, which may help manage chronic conditions associated with inflammation. Some studies suggest that cinnamon may improve insulin sensitivity and help regulate blood sugar levels, although results can vary, and Cinnamon has demonstrated antimicrobial effects against various bacteria and fungi. Rarely, individuals might experience allergic reactions or sensitivity to cinnamon, especially when using concentrated forms like essential oils.

[0070] Cinnamon is a versatile spice with a long history of culinary and medicinal use. It offers various potential health benefits, but it's important to use it wisely and be mindful of the type and quantity consumed. In some embodiments, some or all of these compounds are combined to meet the therapeutic goals of mental health situation targeted and adjusted based on the data obtained from the patient in near real time.

[0071] The PTSD market is evolving with advancements in treatment options, increased awareness, and growing demand for supportive services, reflecting the critical need for comprehensive care for individuals affected by PTSD. It is recognized that there is no medical “cure” for PTSD, or any other form of mental illness, hut a combination of approaches in parallel may offer patients hope and alleviate symptoms.

[0072] There is preliminary clinical use data on the compounded formulation disclosed herein, with a diverse patient targeted demographic. It has surprisingly been discovered that LDN only based therapy as a novel drug therapy alone will not work. The chosen therapies must be adjunctive to a comprehensive approach.

[0073] Preferably, the therapy includes a unique to the market combination of low doses of FDA cleared components, pharmaceuticals, nutraceuticals, and monitoring and therapy within a patient portal of 24 / 7 connectivity between care providers and patients. When used in combination, the approach is uniquely suited to address various common disease states.

[0074] Typically, antidepressants (such as SSRIs and SNRIs) and anti-anxiety medications are used to manage symptoms of PTSD. Specific drugs like sertraline and paroxetine are commonly prescribed. Here, therapies are preferably combined with nutraceuticals based on CBN. Various forms of psychotherapy, including Cognitive Behavioral Therapy (CBT), Eye Movement Desensitization and Reprocessing (EMDR), and trauma-focused therapy, are often components of PTSD treatment. Individual counseling, group therapy, and peer support programs designed to help individuals manage and recover from PTSD may be helpful.

[0075] Additionally, mindfulness practices like yoga and meditation have been reported to help with PTSD. Such practices can be provided through apps for managing PTSD symptoms, by providing therapy exercises, and offering mindfulness and relaxation techniques. Faced with the demands of both a physical and emotional recovery, adaptive yoga allows newly and long-term disabled veterans to reconnect with both themselves and their loved ones. Warriors with PTS, amputations, traumatic brain and spinal cord injuries may benefit from modified yoga practices in conjunction with rest and meditation. Mindful breathing may calm the sympathetic nervous system, which activates the body's "fight-or-flight" response. A growing number of first responders, firefighters, and police officers are exhibiting the symptoms of PTSD, potentially due to many of them taking on public service jobs after retiring from the military. Remote therapy and counseling services (including through apps) that provide accessibility and convenience for individuals seeking treatment for PTSD have become widely accepted. Apps may include near real-time vital sign monitoring in association with a wearable or implantable device.

[0076] There exist specialized programs and services for veterans and active-duty military personnel, including VA facilities and military-focused PTSD treatment programs. Trauma- Informed Care programs incorporate trauma-informed approaches to provide supportive care for individuals affected by PTSD.

[0077] Growing awareness and recognition of PTSD, particularly among veterans, first responders, and individuals experiencing trauma, continue to contribute to higher demand for treatment and support services. This is a hurdle as many with PTSD do not come forward and admit it. This is slowly changing. The prevalence of PTSD is increasing due to factors such as military conflicts, natural disasters, and other traumatic events, driving demand for effective treatment solutions. PTSD is not a “military service” trauma only. Innovations in pharmaceuticals, psychotherapy, and digital health technologies enhance treatment options and support for PTSD patients.

[0078] There is increasing funding and support from governments and other organizations to address PTSD, particularly for veterans and at-risk populations. Integrating of mental health services into primary care and broader healthcare systems improves access to PTSD treatment and support. Preferably, the inventive therapy offers a remote ability to bridge any ongoing current treatment with a comprehensive new approach to render advanced capability to heal from the PTSD and other mental health issues.

[0079] In the preferred embodiment, there is an intemet / online accessible patient portal. The patient portal preferably has a patient facing portion and a back-end portion. Preferably, the patient can access the patient facing portion through an internet connected device (i.e. computer, smartphone, or tablet). In some embodiments, the patient may be able to call into the patient portal. Through the patient portal, the patient is preferably able to monitor their health, track medication, consult with medical and psychological professionals, and watch and / or hear recordings and / or live streams of exercise classes (i.e. yoga), physical therapy exercises, mindfulness exercises, breathing exercises, meditation exercises, and other health information. Preferably, the patient portal is available to the patient 24 hours a day 7 days a week. Preferably, the patient portal includes accessibility features.

[0080] The back-end of the patient portal preferably is accessible to medical and mental health professionals to review patients’ records, prescribe medication and / or therapy, adjust medication and / or therapy, and interact with and contact patients and other users. The back-end may also be accessible by case workers, social workers, instructors, and other care givers. Preferably, the patient portal is HIPPA compliant.

[0081] A medication combination, of Low Dose Naltrexone and a low-dose muscle relaxer may provide a safe, adjunctive relief but not a cure for a multitude of issues including but not limited to addiction, chronic and acute pain, pain related to diabetes, polymyalgia, fibromyalgia, depression, PTSD, and other incurable diseases. The medications may make significant improvements in many lives and reduce the overall need to employ narcotics for relief. Derived from two compounds that have been safely utilized for decades at a dosage far exceeding the microdosing used herein, the effect is deemed to emanate from a natural release of endorphins, a compound known to lessen pain and anxiety and to foster a sense of well-being. The utilization of very low dose Naltrexone (1 to 5 mg) and a muscle relaxer (methocarbamol in low doses of 1 to 10 mg or other equally effective muscle relaxer titrated to the physiological status as monitored 24 / 7) is effective and safe.

[0082] Furthermore, the monitoring platform preferably gains insight on a patient through a wearable or implantable device and is able to dynamically implement / enable therapy strategies effectively and measures impacts of the disease and the treatment in near real time (NRT). In this context, it could be adapted to address aspects of improving and managing medical monitoring systems.

[0083] Preferably the monitoring platform gathers and analyzes data to understand the patient’s health trends and needs. For medical monitoring, this means using data from wearable devices, sensors, or electronic health records to gain dynamic insights into a patient's condition and health trends, which is a tenet of how to treat and what to expect as an outcome. The platform might involve developing new technologies or improving existing ones. For example, this could include advancements in wearable technology, real-time health monitoring systems, or Al algorithms that can better predict health issues before they become critical.

[0084] The monitoring platform may be capable of analyzing the patient’s data and recommending a treatment, changing a treatment, alerting the patient to their state, alerting emergency services, and alerting medical professionals. Treatments may include breathing exercises, mindfulness exercises, grounding exercises, physical exercises, meditation, redirecting focus, or another medical intervention. The alert may be audible (i.e. an alarm), physical (i.e. a vibration), or audible (i.e. a beeping noise). Preferably, the alarm will not deactivate until the patient specifically stops the alarm (i.e. by pressing a button).

[0085] Furthermore, the monitoring platform is preferably coupled to the patient portal. For example, the data obtained by the monitoring platform may be transmitted to the patient portal where the patient and their doctors may be able to review the data. The patient and / or medical professional may be able to adjust thresholds through the patient portal.

[0086] Preferably, the platform is capable of interacting with devices or systems in clinical settings, ensuring they are integrated effectively into existing healthcare practices, and training healthcare professionals to use them effectively. Measuring the effectiveness of the medical monitoring system is built upon improving patient outcomes. Earlier data saves lives. Near real time (NRT) data, both in the military and civilian applications, could be a game-changer for both the care providers and the patients. For example, such data can be used in early detection of health issues, improving patient management, reducing hospitalizations, or enhancing overall patient care.

[0087] As of the latest estimates, approximately 8 million adults in the United States are experiencing post-traumatic stress disorder (PTSD) in any given year. This figure can vary based on different studies and surveys, but it provides a general sense of the prevalence of PTSD among the adult population. In the United States, addiction issues are quite prevalent. According to the National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA), approximately 20.3 million adults (aged 18 and older) had a substance use disorder in 2022. This includes issues related to alcohol, drugs, or both. As of recent estimates from the National Institute of Mental Health (NIMH), about 21 million adults in the U.S. are experiencing at least one major depressive episode per year. For anxiety disorders, around 40 million adults in the U.S. are affected annually. This includes a range of conditions such as generalized anxiety disorder, panic disorder, and social anxiety disorder. These numbers reflect a significant portion of the population and underscore the widespread nature of mental health issues.

[0088] As of August 2024, the estimated population of the United States is approximately 334 million people. According to the Centers for Disease Control and Prevention (CDC), approximately 6 in 10 adults in the U.S. have at least one chronic disease (over 200 million), and 4 in 10 adults have two or more chronic diseases (133.6 million). Chronic diseases include conditions such as heart disease, diabetes, chronic respiratory diseases, and cancer.

[0089] Studies have linked anger as a mediator between stress-related psychological disorders resulting in autonomic dysregulation and harm to oneself or others. The autonomic nervous system (ANS) is the primary mechanism controlling fight-or-flight, which is a physical response to a threat or stressor, real or perceived. ANS dysregulation is a common physiological manifestation of psychological disorders, including post-traumatic stress disorder, panic disorder, major depressive disorder, anxiety, insomnia, and other stress-related disorders. Persistent allostatic overload and autonomic rigidity disable cognition and emotional regulation when presented with even minor stressors, inciting disproportional responses including angry outbursts, aggression, and in extreme cases, bodily harm. Successful management techniques of stress-induced psychological disorders, emotional dysregulation, and subthreshold symptomatology can vary between individuals, but awareness of sympathetic dominance and heightened arousal predicates any intervention. Early detection of sympathetic activation reduces stress response duration, limiting its magnitude and expression. Physiological monitoring can not only detect and alert to heightened arousal and sympathetic dominance, but can also be used to evaluated allostasis, autonomic flexibility, and stress resilience. In a simple understanding, an internal cognitive or external buddy system to assist the individual recognize the patterns is lacking.

[0090] Preferably, herein, physiological indicators are used as a tool to teach and promote biological and emotional regulation, as well as an objective, systematic way of assessing mental fitness and stress-resilience for active duty and / or reintegration into civilian life. The current invention also may include an innovative patient portal. The program is used to combat comorbid mental health, domestic violence, and suicide crisis by leveraging current capabilities with new technology for a long-term homehealth wearables system. This program effectively deploys an individual’s preferred intervention(s) and facilitates adaptive behavior in veterans and military personnel. Subjects are preferably equipped with a smart watch (or other wearable or implantable) connected to the application on their phones (or other Internet connected device), for continuous physiological monitoring. Preferably, participants will denote mental state on an emotional scale daily with the option to leave more detailed feedback and be interviewed weekly (or as-needed) to report on efficacy. Remote connectivity preferably allows continuous program assessment for prompt responses to feedback. Devices can be updated remotely to mitigate resource waste. The system may be designed for continued accessibility, specifically for those with limited resources, conflicting, comorbid, or undiagnosed conditions, and / or in remote areas. The treatment can be used by veterans in the workforce struggling with daily stressor, rehabilitation facilities, reoccurring prisoners, social workers supporting refugees with trauma, veteran aid organizations, and more.

[0091] The system aims to empower patients to cope with stressors in real-time, during everyday situations by training a pause. It is not uncommon for those with anger issues, trauma, or stress-related conditions to fail to recognize dysregulation. Subjects are notified when a heightened state is sensed and can learn to identify and recognize when they are in a fight-or-flight mode from an objective, non-confrontational source. Subjects preferably have decision support at hand through the system to assist in selecting a coping mechanism, intervention therapy, or connecting them to a help line while their internal cognition may be impaired by sympathetic dominance. Customizable decision flow comes with default evidence-based therapies that can be altered to the preference of each user. Furthermore, extended periods of sympathetic dominance have been shown to induce depression and depressive symptoms over time. Thus, early notification may also help circumnavigate long-term severity of depression by raising awareness and assisting in down-regulation.

[0092] Output from wearables can also provide systematically implementable insight on a subject’s risk factor to themselves or others, their ability to maintain allostasis through the presence of a stressor, and ability to down-regulate. Autonomic dysregulation and heightened arousal are closely tied to anger, aggression, and impulsiveness, and have been observed in perpetrators of domestic abuse.

[0093] The assessment capabilities of the system preferably extend to psychological fitness screenings to inform return to activity, active duty, and / or transition to civilian life. Psychological fitness characterized by physiological output in military personnel is not a new concept. However, a single variable measurement may fail to account for all possible influencing factors within such a diverse population. Rather, this program preferably uses a cumulative approach to psychophysiological profile where parameters are weighted into a summary state calculation that can be more systematically applied. Data collected preferably supplements screening of each subject for mental fitness, PTSD, and symptoms associated with dysregulation leading to anger, aggression, and outbursts, as well as indicating a subject’s ability to function adequately under stress, both the extreme stress of tactical operations and the everyday stress of civilian life.

[0094] Preferably, a wearable multi-parameter vital signs sensing / status / alarm indicator is connected to an Android watch. The system preferably offers an adaptive warning indication of compromise, trending and risk. The set of vital signs (skin temperature, SpO2, HR, Respiration Rate (RR)), are preferably used to evaluate the condition of the wearer.

[0095] In the preferred embodiment, a nutraceutical with a formulation of 3 mg THC, with 2 mg CBG (Cannabigerol) and 1 mg CBD, is combined with a pharmaceutical of 4.5 mg naltrexone, 4.5 mg methocarbamol. Preferably both the nutraceutical and the pharmaceutical have a filler of natural (Ceylon) cinnamon. While specific doses are shown, the doses can be higher or lower by 10%, 50%, 100%, 200% or more. Additionally, it is possible to replace certain ingredients with other, similar ingredients. For example, CBG and / or CBD can be replaced by CBN. Additionally, the filler may be replaced with an inactive filler. Methocarbamol may be replaced with another pain reliever.

[0096] Both methocarbamol and THC are central nervous system (CNS) depressants, meaning they can cause drowsiness, dizziness, and impair motor coordination and cognition. LDN is prescribed in a very low dose of an opioid antagonist, typically used off-label for chronic pain, inflammation, or autoimmune conditions. In this dose, reports indicate it stimulates endogenous endorphin release. THC and LDN do not have any direct contraindicated interaction. LDN may modulate the endorphin system, and THC also affects the endocannabinoid system, both of which can influence mood and pain perception. Methocarbamol and LDN are both used in pain management (one as a muscle relaxant, the other potentially for chronic pain), so they may be used together and appear to complement each other.

[0097] Preferably, the formulation is started at a lower dose and effects are monitored, especially if the patient is new to any of these substances. Titration in patients is preferred. For example, the titration may ramp up LDN from 1.5 to 3.0 to 4.5 mg / day over two, three, or four weeks. The pharmaceutical can be taken without the nutraceuticals and the nutraceuticals can be changed or taken without the pharmaceutical. The pharmaceutical and nutraceuticals can be combined in one pill or other delivery mechanism or they can be separated in to two or more pills and / or delivery mechanisms. Preferably, the titration planned will be monitored both on site and remotely and any adverse effects so noted. If the patient already uses THC or a similar nutraceutical for their own therapy, adding more THC is likely a higher concern than if they do not already use THC. Since patients may not be truthful about THC use, titration preferable as is the monitoring plan. Preferably, patients are monitored for: vital signs including HRV / HRC, confusion, drowsiness, mood changes, sleep disturbances, and / or blood glucose levels.

[0098] Preferably the formulation is up to 4.5 mg methocarbamol and up to 4.5 mg naltrexone and 3 mg THC / day with complementing CBG (2 mg / day) and CBD (1 mg / day). Clinically, this stack, known as a 3-2-1 combination, and although it is very low dose it makes a difference. Surprisingly such a treatment produces tremendous results on a very low dose of these drugs in pilot studies.

[0099] • Methocarbamol: 4.5 mg (extremely low microdose. Standard doses arc usually 500-1500 mg).

[0100] • Low-Dose Naltrexone (LDN): 4.5 mg (a common and typical LDN dose).

[0101] • THC: Up to 85 mg per dispenser pack over 28 days so a typical dose is 85 / 28 or 3.04mg / day

[0102] • CBG: Up to 56 mg per dispenser pack over 28 days so a typical dose is 56 / 28 or 2 mg / day

[0103] • CBD; Up to 28 mg per dispenser pack over 28 days so a typical dose is 28 / 28 or 1 mg / day

[0104] Low-Dose Naltrexone (LDN) is typically used for and has been FDA cleared for chronic pain, autoimmune conditions, or inflammation (e.g., fibromyalgia, MS, Crohn’s). At the dose described herein, it is not blocking opioids fully but is believed to modulate the immune system and increase endogenous endorphins. LDN is generally well-tolerated, though some people experience vivid dreams, insomnia, or agitation at first. LDN can stabilize mood in some people by boosting endorphin levels, which may indirectly improve resilience, calmness, and well-being. It has been used off-label in some people with depression, PTSD, bipolar disorder, or chronic pain who have suicidal thoughts. Effects may build over time (days to weeks), so consistency matters. LDN may help regulate endorphins and reduce emotional extremes, including suicidal ideation.

[0105] Methocarbamol is preferably given at an unusually low dose. Standard tablets are 450-500 mg. The pharmaceutical has preferably l / 100th of the typical clinical use dose. Using a very low dose, it may function like a mild CNS relaxant rather than a muscle relaxant. At low doses, it may reduce anxiety -related muscle tension or agitation without strong sedation. There’s very limited research on methocarbamol for anxiety or mood, but in low doses, it might help as an adjunct (like some people use magnesium or GABA analogs). At this very low dose methocarbamol could help reduce physical restlessness, body tension, or agitation without full sedation. It is used at a sub-clinical efficacy dose but is still effective.

[0106] The THC dose is preferably up to 6 mg / day (two doses per day). Moderate to high doses of 15-30 mg may be used if patient already uses cannabis or cannabis derived drugs. Doses of over 50 mg is usually only for tolerant users (e.g., medical cannabis patients with chronic pain or cancer). THC can be biphasic: Low doses (1-10 mg) are often calming or mood-enhancing and sleep supportive, while high doses (>30 mg) can worsen anxiety, cause paranoia, or trigger mood instability, especially in people with a history of suicidal ideation or psychiatric vulnerability. Chronically high THC use may blunt natural dopamine / serotonin responses over time. THC (tetrahydrocannabinol), the psychoactive compound in cannabis, can sometimes interrupt rumination — the repetitive, often negative thinking pattern common in anxiety, depression, and PTSD.

[0107] THC disrupts default mode network (DMN) activity. The DMN is a brain network involved in self-referential thought and mind-wandering, often active during rumination. Rumination is a mental process where someone repeatedly thinks about the same distressing thoughts, problems, or feelings, often in a loop — and without finding relief or solutions. It increases anxiety and depression by reinforcing negative thoughts, it keeps our brain in a stress response loop, and it can amplify suicidal ideation, especially if the patient feels trapped in their thinking. THC has been shown to reduce activity in the DMN, which may help "break the loop" of repetitive thoughts. THC has acute anxiolytic & mood- altering effects. At low doses, THC can reduce anxiety and elevate mood, offering emotional relief from spiraling thoughts. This "mental shift" can allow someone to step back from obsessive thinking and gain new perspective. THC alters time perception & focus. THC can distort sense of time and shift attention, pulling focus away from internal monologue. This can intermpt the flow of ruminative thinking by changing how thoughts a e ordered or experienced. THC provides increased sensory engagement. THC often heightens sensory input — music, visuals, touch, etc. This external sensory pull can shift awareness out of the internal mental loop and into the present moment, similar to mindfulness techniques. Adding CBG (cannabigerol) and CBD (cannabidiol) to the THC in low doses can significantly change how the body and mind respond to the low dose THC — and often for the better, especially in the context of anxiety and suicidal ideation. CBD is non-psychoactive, and reduces anxiety, paranoia, and excessive stimulation from THC. CBD acts on 5-HT1A serotonin receptors, helping with mood stabilization and emotional regulation. It also modulates THC effects — makes the high less intense, more ‘‘mellow.” CBD can reduce rumination, which is key for people managing suicidal ideation. CBG is the less well-known of the cannabinoids. It is mildly uplifting and possibly has anti-depressant-like characteristics via adrenergic and serotonin mechanisms. It has been shown in early studies to reduce anxiety and increase motivation / energy without strong stimulation. CBG may help with emotional resilience and focus (some report it helps with ADHD symptoms). Synergistic with CBD and CBG is less sedating than THC or CBD. CBG in unison with CBD smooths out the THC “experience” and may help maintain emotional regulation. Patients typically will simply feel “good” but not high. Patients may feel more functional, less foggy, and have lower peaks and valleys in mood. This is especially helpful for managing emotional volatility, rumination, and suicidal ideation triggers. With this formulation the THC is balanced and this balance may make the dose of THC less emotionally risky even if taken twice or three times a day. The dose creates euphoria not a high or psychedelic state. Table 1 shows the synergistic effects and risks of combining THC, CBD, and CBG.

[0108]

[0109] Table 1

[0110] Some preliminary studies on Natural Cinnamon (Ceylon) as a filler show antioxidant and anti-inflammatory effects that may support mood indirectly. It is not typically used as a primary treatment, but can be part of a holistic approach. It may be a gentle natural support.

[0111] Example:

[0112] Ten (10) military veteran participants, were recruited for a study and upon acceptance provided pharmaceuticals and nutraceuticals in addition to 24 / 07 access to therapies consisting of mental health expertise, yoga and meditation a wearable vital sign recording and acquisition system of consisting of a wearable wrist monitor and a mobile phone for cloud-based upload of data.

[0113] Data was acquired pre-treatment as a baseline for about a week and then post therapies to determine a preliminary efficacy score of the program. Overall pilots compiled 4-6 weeks of data. Overall instability of vital signs pre-therapy was significantly greater and showed a nominal reduction in volatility and stress of nearly 60% with therapy. While some participants showed a fairly stable pre-therapy statistical relationship and some showed extreme volatility in pre-therapy data, all showed trends to the more positive as follows: a. Decrease in heart rates on average by 18 = / - 10 bpm b. Increase in HRV / HRC by 10 to 30% c. Increased trend to higher SpO2 during treatment, which may indicate a potential improvement in cognition (or a reversal of cognitive decline) d. Decrease in RR by 5 = / -4 bpm e. Decrease in stress score by 20-60%. f. Improved recovery rates of stress reaction (cause of stress was not documented in the pilot)

[0114] Nearly 100% of the participants reported positive outcomes early and consistently on the program in the 4-6 week study and voiced desire to continue treatment after the pilot ended. A significant number of testimonials have been received on the treatment by both pilot study participants and other civilians paralleling the results of the pilot.

[0115] Table 2 summarizes mathematically data received from the participants and trends that can be identified (a multiplier)- derived from trauma care (seriously injured). The data reveals that psychology may manifest in physiological data. Critical but stable versus critical and failing versus highly volatile inputs (unstable) are different. For example, a participant with critical vitals trending negative is in a different state than one with critical but stable vitals (i.e., he / she is perhaps exercising / working hard).

[0116]

[0117] Table 2

[0118] As an example, the participants heart rate alone is not the whole picture. A stress response would perhaps vary from an exercised response and recovery. For example, figure 1 depicts an example of heart rate changes and the participant’s fatigue and recovery. This is a normal reactive process. The algorithm preferably can predict the rate of HR fatigue and recovery to “tease” the stressor response out of the data for workload increases. Rate of change compares past and present values to evaluate if the patient’s health is improving or deteriorating. The slight irregular pattern of heart rate is described by heart rate variability and heart rate complexity, which is controlled by the autonomic nervous system. How vitals change is often more important than the values to which they change. In a study of sudden death patients, a majority had a sudden deterioration in vitals, frequently blood pressure. It is common practice to track the improvement or deterioration of a patient’s vitals that is suffering from a traumatic brain injury (TBI). Any sudden deterioration of a patient with a TBI requires prompt attention and treatment. Vitals tracking of acutely ill patients is usually not as rigorous. Patients, who seem fine, may not be examined in such great detail. For this reason, a rate of change parameter was included and preferably will be able to incorporate the information on how the vitals change in the summary alarm, as well as inform a medical professional if a patient is deteriorating, and which vital / s are deteriorating.

[0119] In the study, each vital had an associated amount it can increase or decrease within two minutes before notifying a medic. Each amount is specific to each particular vital. For example, if the blood pressure dropped 10%, it could be caused by something as small as a change in position, where as if the oxygen saturation were to decrease by 10% that would indicate that patient is in a serious condition and needs immediate attention.

[0120] SpO2 was acquired during the study, which alone does not tell the acute or chronic story for participants. Long term, even mild hypoxia can impair cognition, which may be a key parameter of functional ability to complete mental tasking effectively. Every living tissue in the body needs oxygen and nutrients to function. These essentials are distributed through the body via the circulatory system. A lack of oxygen or inability of a tissue to utilize the oxygen is called hypoxia. Hypoxia can occur because of posture, low hemoglobin, CO poisoning, and altitude. Normal oxygen saturation is between 90-99%, depending on altitude, but for most, healthy is between 95-98, and 91-94% is considered mild hypoxia. Oxygen saturation under 90% cannot provide sufficient oxygen for all the cells of the body, and oxygen saturation under 85% cannot provide enough oxygen for the vital organs. Hypoxia is present in numerous types of shock and stress responses. Hypovolemic and cardiogenic shock cause hypoxia through an insufficient amount of blood being able to reach body parts. Neurogenic, septic, and psychogenic shock dilate blood vessels, decreasing blood pressure, therefore slowing the transportation of the oxygen rich blood. Also, respiratory shock causes hypoxia, by not presenting sufficient oxygen to the hemoglobin at the lungs. Figure 2 depicts a chart of a decreased cognition model based on the level of SpO2.

[0121] Consistent HR data was acquired. Heart rate and change and volatility are key to patient status. Heart rate is one of the most commonly measured vital signs. It can be found with a finger and a watch. The normal adult resting heart rate is between 60- 100 beats per minute (bpm), though a trained athlete may have a resting heart rate as low as 40 bpm. When the heart beats too fast or too slow, blood docs not effectively travel through the body’s circulation, creating a hypoxic condition. Once this condition affects the body’s vital organs, they will begin to fail.

[0122] The heart rate may become tachycardic (abnormally high) during stress as it does during a hemorrhage, hypoglycemia, sepsis, dehydration, shock, or snake bites, attempting to move more blood and nutrients through the body. At some point, the increased rate of pumping, does not allow sufficient time for adequate ventricular preload for the heart, and therefore less blood is pumped from the heart. In addition to the decreased blood flow and blood pressure, the heart, which is now working harder to pump more often, requires more oxygen for metabolism, which reduces the blood flow to other areas of the body, increasing the risk of ischemia that may result in an infection. Bradycardia, on the other hand, which is a heart rate that is significantly slower than normal, causes an inefficient amount of oxygenated blood to be present in the circulatory system. It is most often identified as heart failure. As opposed to tachycardia, when the filling time is shortened, during bradycardia the long ventricular preloads may lead to an overextension of the ventricles. Some causes of bradycardia include intercerebral hemorrhage, heart attack, dilated cardiomyopathy, and marine animal stings or bites.

[0123] Skin temperature was acquired from the wearable. This is a common vital used to determine if someone is sick (typically a febrile episode). The normal core body temperature is approximately 37°C (98.6°F), varying slightly person to person, as well as by time of day. In many cases, the skin temperature will be used by wearables because of its ease of access. Normal skin temperature is slightly lower around 32-34°C (89.6-93.2°F). When the body temperature is lower or higher than normal it is described as hypothermia and hyperthermia, respectively.

[0124] Hyperthermia is very serious because high body temperatures cause increased metabolism expenditure, exhausting the patient’s energy. It usually occurs in the form of a heat stroke or heat exhaustion. This can precipitate out of stress reactions. Heat exhaustion usually occurs while exercising in a hot environment, as it is caused by the inability to cool the body. Symptoms are commonly heavy sweating, paleness, muscle cramps, tiredness, weakness, vomiting, or fainting. A heat stroke is similar, but also involves symptoms of confusion, seizures, or unconsciousness. Hyperthermia has also been associated with post traumatic cerebral inflammation, hypothalamic damage or infection. During a fever, the body increases body temperature in order to attempt to denature viral proteins. Unfortunately, most proteins, including those in the human body, denature at 40°C (104°F). Hyperpyrexia is especially dangerous to the cells of the brain and heart, as they cannot rejuvenate.

[0125] Hypothermia occurs when the body temperature is colder than normal, which occurs in cold environments, shock, alcohol or drug use, and some metabolic disorders. It can cause shivering, lethargy, confusion, and coma. Hypothermia slows all physiological conditions including heart rate, respiration, nerve conduction, mental acuity, neuromuscular reaction time, and metabolic rate. This slow metabolism allows cells to survive longer without oxygen. One study on the effects of shock on rats, found that rats with a lower tissue temperature had significantly less brain damage from the induced shock, than those high tissue temperature. Though hypothermia has detrimental effects, such as increased susceptibility to infection because of the depressed immune system, the risk of mild cooling is minimal, especially for patients with a poor outlook.

[0126] Respiratory Rate (RR) was indirectly obtained from the watch’s SpO2 sensor. Breathing is essential for oxygenation of blood and can significantly change with anger and anxiety. Normal breathing rate is 12-20 breaths / min. Breathing brings in oxygen for the blood and releases the carbon dioxide waste from the body. The body contains chemoreceptors to regulate the amount of oxygen and carbon dioxide in the blood. When the body is hypocarbia or hypoxaemia it will increase tidal volume, respiratory rate, and alveolar ventilation. This is directed by the autonomic nervous system (ANS) and can be monitored by the HRV (Heart Rate V ariability) and / or HRC (Heart Rhythm Complexity). If the body begins hyperventilation, breathing too deep or too fast, CO2 levels decrease in the body, which reduces blood flow to the brain. Though the overall cause of hyperventilation is unknown, it is common during an infection, bleeding, and heart attacks. Hyperventilating patients may be dizzy, confused, agitated, hallucinate, or faint. Hyperventilation also causes a drop in calcium which can cause numbness or tingling of arms and mouth, and muscle twitching, spasms or cramps of feet or hands.

[0127] One study found that respiration rate was a good indicator of the stableness of a patient. They found that relative changes in respiration rates were higher than heart rate and systolic blood pressure between patients of varying health conditions. From the study, the authors recommended that patients with a respiration rate higher than 24 breaths / min should be monitored, and patients with a respiration rate higher than 27 breaths / min should receive immediate attention.

[0128] Figure 3 depicts a participant’s representative data plot of stability prior to trial initiation. The first few days in the pilot were used as a stability and data acquisition check. The participant’ s data is linear and stable even though there were, as expected, some volatility, especially on heart rate (expected and normal). Figure 4 depicts a participant’s data file pre- and post-therapy, pre- and post-therapy divided by black vertical dashed line. Figure 5 depicts the data of the same participant as in figure 4, showing a volatility abrupt change in data files after treatment starts depicted by the vertical black dotted line on Day 5. Figures 4 and 5 show a consistent impact of the comprehensive treatment. As depicted herein, the volatility on each parameter in this participant is markedly obvious pre and post treatment. A surprising yet typical participant result. In addition, the reduction in CSSI trends shows the participant is overall better off than pre-treatment.

[0129] Figure 6 depicts a chart of a patient’ s data with trending lines statistically inserted. Note the trend to reduction in HR and stress. Figure 7 depicts a chart of the volatility in a participants data file, focused in on stress which in also manifested in tachycardia (124 bpm). The study’s objectives were all met or exceeded and, based on the participant data, the therapy works and works surprisingly better than expected.

[0130] Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. All references cited herein, including all publications, U.S. and foreign patents and patent applications, are specifically and entirely incorporated by reference. The term comprising, where ever used, is intended to include the terms consisting and consisting essentially of. Furthermore, the terms comprising, including, and containing are not intended to be limiting. Tt is intended that the specification and examples be considered exemplary only with the true scope and spirit of the invention indicated by the following claims.

Claims

Claims1. A mental health treatment system, comprising: a pharmaceutical; a nutraceutical; a wearable patient monitoring device; and a remote patient portal adapted to receive data from the patient monitoring device; wherein the patient portal provides the patient access to health professionals and health materials.

2. The mental health treatment system of claim 1, wherein the pharmaceutical comprises a Low-Dose Naltrexone (LDN) and a muscle relaxant.

3. The mental health treatment system of claim 2, wherein the muscle relaxant is one of Methocarbamol and Cyclobenzaprine.

4. The mental health treatment system of claim 1, wherein the nutraceutical is comprised of at least one derivative of cannabis.

5. The mental health treatment system of claim 4, wherein the nutraceutical comprises at least one of THC (tetrahydrocannabinol), CBG (cannabigerol) and CBD (cannabidiol).

6. The mental health treatment system of claim 1, wherein the wearable comprises at least one sensor, each sensor adapted to obtain at least one of skin temperature, SpO2, heart rate (HR), and respiration rate (RR) data.

7. The mental health treatment system of claim 6, wherein the wearable comprises at least one of an audible, physical, or optical alarm adapted to alert the patient to data outside a predetermined threshold.

8. The mental health treatment system of claim 1, wherein the patient portal is Internet accessible.

9. The mental health treatment system of claim 1, wherein the patient portal provides the patient with at least one of health monitoring, medication tracking, medical and / or psychological professional consultations, and access to recordings and / or live streams of exercise classes, physical therapy exercises, mindfulness exercises, breathing exercises, and meditation exercises.

10. The mental health treatment system of claim 1, wherein a daily dose of the pharmaceutical is comprised of 4.5 mg of methocarbamol and 4.5 mg of low- dose naltrexone (LDN), and a daily dose of the nutraceutical is comprised of 3.04 mg THC, 2 mg of CBG, and 1 mg of CBD.

11. The mental health treatment system of claim 1, wherein at least one of the pharmaceutical and the nutraceutical comprises a natural cinnamon (Ceylon) filler.

12. A method of treating a mental health patient, comprising the steps of: prescribing a pharmaceutical to the patient; prescribing a nutraceutical to the patient; providing a wearable patient monitoring device to the patient; and providing a remote patient portal adapted to receive data from the patient monitoring device; wherein the patient portal provides the patient access to health professionals and health materials.

13. The method of claim 12, wherein the pharmaceutical comprises a Low-Dose Naltrexone (LDN) and a muscle relaxant.

14. The method of claim 1 , wherein the muscle relaxant is one of Methocarbamol and Cyclobcnzaprinc.

15. The method of claim 12, wherein the nutraceutical is comprised of at least one derivative of cannabis.

16. The method of claim 15, wherein the nutraceutical comprises at least one of THC (tetrahydrocannabinol), CBG (cannabigerol) and CBD (cannabidiol).

17. The method of claim 12, wherein the wearable comprises at least one sensor, each sensor adapted to obtain at least one of skin temperature, SpO2, heart rate (HR), and respiration rate (RR) data.

18. The method of claim 17, wherein the wearable comprises at least one of an audible, physical, or optical alarm adapted to alert the patient to data outside a predetermined threshold.

19. The method of claim 12, wherein the patient portal is Internet accessible.

20. The method of claim 12, wherein the patient portal provides the patient with at least one of health monitoring, medication tracking, medical and / or psychological professional consultations, and access to recordings and / or live streams of exercise classes, physical therapy exercises, mindfulness exercises, breathing exercises, and meditation exercises.

21. The method of claim 12, wherein a daily dose of the pharmaceutical is comprised of 4.5 mg of methocarbamol and 4.5 mg of low-dose naltrexone (LDN), and a daily dose of the nutraceutical is comprised of 3.04 mg THC, 2 mg of CBG, and 1 mg of CBD.

22. The method of claim 12, wherein at least one of the pharmaceutical and the nutraceutical comprises a natural cinnamon (Ceylon) filler.

Citation Information

Patent Citations

  • Medication and Treatment for Disease

    US20110217278A1

  • Compositions and methods for the treatment of somatosensory disorders

    US20110245208A1

  • Sweetening and Healthy Compositions and Methods Associated Therewith

    US20140255367A1

  • Topical regional neuro affective therapy with cannabinoid combination products

    US20190343760A1

  • Cancer treatment comprising naltrexone and a cannabinoid

    US20220143010A1